#AAD2019

IN 77TH AAD CONGRESS

1-5 MARCH 2019

* WASHINGTON *

Scientific Initiative of:



Sponsored by:

U NOVARTIS



* WASHINGTON *

Pediatric dermatology: Dr. Oriol Corral Magaña

Scientific Initiative of:


Sponsored by:



F028: NURSERY TALES: CHALLENGING DERMATOSES IN NEWBORN (DR. RAEGAN)

#AAD2019

AAF




Adapted from F028. Dr. Raegan

Zhao CY, Murrell DF. Autoimmune blistering diseases in females: a review. International Journal of Women's Dermatology. 2015 Feb;1(1):4–12.

F028: NURSERY TALES: CHALLENGING DERMATOSES IN NEWBORN (DR. HUNT)

CM & Sturge Weber Syndrome

- RMI is better predictor than localization for neurologic outcomes.
- For practical reasons guidelines based on clinical phenotype are used. The best clinical predictor for adverse outcomes are forehead lesions.





- RMI prior to 6 month have not demonstrate better outcome.
- False negative exists. Neurologist follow up is adviced.

DOI: 10.1111/pde.13304



-5 MARCH 2019

#AAD2019

Screening for Sturge-Weber syndrome: A state-of-the-art review

```
Michaela Zallmann MBBS<sup>1,2</sup> | Richard J. Leventer MBBS, PhD<sup>2,3,4</sup> | Mark T. Mackay MBBS, PhD<sup>2,3,4</sup> | Michael Ditchfield MBBS, MD<sup>5,6</sup> | Philip S. Bekhor MBBS<sup>7</sup> | John C. Su MBBS, MA, MSt, MEpi, MBA<sup>1,2,4,7</sup>
```

S025: CHALLENGING ADULT & PEDIATRIC AUTOIMMUNE CONNECTIVE TISSUE DISEASES CASES: PEARLS FOR DIAGNOSIS & MANAGEMENT

SAVI: Sting Associated Vasculopathy with onset in Infancy (Dr. Ho)

• Systemic disease with skin vasculopathy, ILD and systemic inflamation.

#AAD2019

5 MARCH 2019

• Good cutaneous response with JAK inh.

Dermatomyositis clinical pearls:

- Facial erythema can be very similar to SEL and histology can not distinguish both entities. Nasogenian involvement is not present in Lupus (Dr. Abeer).
- In Amyopathic DM only 10% of patients will respond to antimalarial alone. Combination of antimalarial or adjuvant use of other imunosuppressive treatments (MTX, MMF) may be necessary. IVIG present good outcomes (Dr. Cobos)
- Emerging therapies: Tofacitinib (JAK inh) shows promising results.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation. 2018 Jul 2;128(7):3041–52.

Kerrigan SA, McInnes IB. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes? Current Rheumatology Reports [Internet]. 2018 Dec;20(12). Available from: http://link.springer.com/10.1007/s11926-018-0792-7

Kurtzman DJB, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatology. 2016 Aug 1;152(8):944.

S025: CHALLENGING ADULT & PEDIATRIC AUTOIMMUNE CONNECTIVE TISSUE DISEASES CASES: PEARLS FOR DIAGNOSIS & MANAGEMENT

Juvenile Dermatomyositis Pearls (Dr. Vleugels):

• Not need to routinely run out malignancies, neither lung disease (important in anti-MDA5 DM in adults).

#AAD2019

* WASHINGTON

- Early and aggressive treatment must be initiate to avoid calcinosis.
- Follow up! True amyopathic disease is rare.

Crohn, infliximab and psoriasis-like dermatitis (Dr. Coughlin & Dr. Patel)

- 10,1% of patients.
- Pruritic & painful.
- Scalp > retro-auricular
- Switch to Adalimumab or Ustekinumab improve lesions.

S025: CHALLENGING ADULT & PEDIATRIC AUTOIMMUNE CONNECTIVE TISSUE DISEASES CASES: PEARLS FOR DIAGNOSIS & MANAGEMENT

Segmental Stiff Skin Syndrome (SSS) (Dr. Kurtzman)

- Rare. FBN-1 mutation. Typically presents in childhood.
- Mimics cutaneous systemic sclerosis. Hard skin around the pelvic or shoulder girdle.

#AAD2019

5 MARCH 20

- Without systemic involvement, but can cause joint contracture.
- No definitive treatment.
- Reported personal good experience with MMF (13^o improvement in articular extension)